Morepen Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−0.3%+7.2%+19.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−27.8%+9.7%+99.4%
−38.5%+15.9%+142.5%
−19.6%+22.7%+148.6%
−21.4%+17.0%+144.2%
+8.9%+37.5%+16.5%
+5.1%+40.1%+12.6%
+1.8%−56.3%+180.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MOREPENLAB₹119.31

Morepen Laboratories Limited

· Pharma & Health
₹ CrorePeersIOLCPINNOVACAPFDCORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,537 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+19.3+7.2-0.3—
EBITDA Growth—+99.4+9.7-27.8—
EBIT Growth—+142.5+15.9-38.5—
Net Income Growth—+148.6+22.7-19.6—
EPS Growth—+144.2+17.0-21.4—
Total Assets Growth—+16.5+37.5+8.9—
Total Equity Growth—+12.6+40.1+5.1—
Cash from Operations Growth—+180.5-56.3+1.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.